| Ticker | Mentions | Stance | Conv | Entry | P&L YTD | Theme | Thesis (click to expand) | Mentioned | Src |
|---|---|---|---|---|---|---|---|---|---|
| MSOS | ×1 | LONG | MED | $4.28 | Healthcare | The potential federal rescheduling of cannabis to Schedule III is a major positive catalyst that will improve access and research, benefiting established operators producing high-quality indoor flower as state-level legalization continues to expand. | Apr 20 | YOUTUBE |